The pharmaceutical company says data on 10 deaths and more than 100 hospitalizations comes from the FDA’s adverse event reporting database for semaglutide — the key ingredient in Ozempic and Wegovy, ...

Novo Nordisk reported earnings, posting some chunky year-over-year growth and far outperforming its only real rival at the ...

Lars Fruergaard Jørgensen, Novo Nordisk CEO, joins 'Money Movers' to discuss Jorgensen's comments on demand in 2025, if demand is waning for GLP-1 drugs, and much more.

The head of the company that makes the diabetes and obesity drugs Ozempic and Wegovy has warned that compounded versions of ...

Novo Nordisk (NVO) has released an update. Novo Nordisk has disclosed share transactions by its board members and executives, highlighting a significant purchase of 1,400 American Depositary Receipts ...

Novo Nordisk (NVO) is aware of 10 deaths and 100 hospitalizations of people that took copycat versions of its popular drugs ...

Danish pharmaceutical company Novo Nordisk (NYSE: NVO) is pioneering a new wave of medical treatment for diabetes and obesity care. The company develops a long line of blockbuster glucagon-like ...

This marks Novo Nordisk's second win this year in treating cardiovascular disease. The company develops a long line of blockbuster glucagon-like peptide-1 (GLP-1) agonists, including Ozempic ...

Shares in Novo Nordisk A/S (DK:NOVO.B) have lost a fifth of their market value since the end of June, the point at which the Danish pharma group revealed that it was committing around $4bn (£3.2bn) to ...

Novo Business Checking Review (2024): Is Novo a Trusted Bank? Your email has been sent You might be wondering if Novo is the right fit for your business? In the following sections we’ll be ...